12:00 AM
 | 
Feb 27, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Pyramax pyronaridine-artesunate regulatory update

EMA's CHMP issued a positive scientific opinion recommending use of Pyramax fixed-dose pyronaridine/artesunate from Shin Poong to treat acute, uncomplicated malaria infection caused by Plasmodium falciparum or by P. vivax in adults and children >=20 kg as a single 3-day treatment course in areas of low...

Read the full 207 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >